Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Monte Rosa Therapeutics to participate in investor conferences
  • Monte Rosa Therapeutics, a biotech company, will participate in investor conferences including the TD Cowen 7th Annual Fall Oncology Innovation Summit and Jefferies London Healthcare Conference. The webcasted presentation will be accessible on the company's website.
  • None.

BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:

  • TD Cowen 7th Annual Fall Oncology Innovation Summit (virtual) – Fireside Chat, November 3, 2023, 1:00 p.m. ET
  • Jefferies London Healthcare Conference (London, UK) – Investor meetings, November 14-15, 2023

The webcasted presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at, and an archived version will be made available for 90 days following the presentation.

About Monte Rosa

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond.  For more information, visit

Andrew Funderburk, Kendall IR

Cory Tromblee, Scient PR

Monte Rosa Therapeutics will participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit and Jefferies London Healthcare Conference.

The webcasted presentation can be accessed on Monte Rosa's website.
Monte Rosa Therapeutics Inc


GLUE Rankings

GLUE Latest News

GLUE Stock Data

Biological Product (except Diagnostic) Manufacturing

About GLUE

small molecule protein degraders are set to reshape the way by which diseases will be treated. our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. headquartered in boston with additional laboratory facilities in basel, monte rosa therapeutics is a private company launched in 2020. initially seeded by versant ventures and incubated at ridgeline discovery in basel, and the institute of cancer research in london, monte rosa has raised $32.5 million from versant and new enterprise associates. academic co-founders are prof. raj chopra and prof. ian collins of the institute for cancer research, uk.